查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565909

全球再生醫學市場：市場規模、佔有率、預測、趨勢分析 - 依產品、依應用、依最終用戶、預測（～2031年）

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product Application End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 248 Pages | 訂單完成後即時交付

價格

2024-2031年，全球再生醫學市場規模預計將以21.5%的年複合成長率成長，到2031年將達到372.7億美元。

本報告經過廣泛的二級和一級研究以及對市場情景的詳細分析，對關鍵行業驅動因素、限制因素、挑戰和機會進行了分析。

全球再生醫學市場的成長是由越來越多的新再生醫學批准、再生醫學的進步、慢性病盛行率的上升、再生醫學開發資金的增加以及新治療領域的再生醫學所推動的。背後的驅動力是其應用的擴展。然而，與幹細胞相關的高昂治療成本和倫理問題限制該市場的成長。

此外，個人化醫療需求的不斷成長、器官移植手術數量的增加以及再生醫學強大的產品線預計將為市場成長創造機會。然而，不利的償付政策、再生醫學製造的複雜性以及缺乏再生醫學安全性和有效性的標準化框架是全球再生醫學市場的主要挑戰。

本報告是基於對過去 3-4年（2020-2024年）產業主要市場參與者所提供的產品組合、區域格局和關鍵策略發展的廣泛評估，提供了競爭格局。參與再生醫學市場的主要公司有Novartis AG（瑞士）、Biogen Inc.（美國）、Kite Pharma, Inc.（美國）、Spark Therapeutics, Inc.（美國）、Integra LifeSciences Corporation（美國）、Sarepta Therapeutics、 Inc .（美國）、Takeda Pharmaceutical Company Limited（日本）、Amgen Inc.（美國）、CORESTEMCHEMON Inc.（韓國）、Smith & Nephew plc（英國）、Vertex Pharmaceuticals Incorporated（美國）、CSL Behring, LLC（美國） ）、Janssen Global Services, LLC（美國）、Medtronic plc（愛爾蘭）、AbbVie Inc.（美國）、Bristol-Myers Squibb Company（美國）、Ferring Pharmaceuticals A/S（瑞典）、Pfizer Inc.（美國）、bluebird Bio Inc.（美國）和Vericel Corporation（美國）。

在本報告調查的所有產品中，細胞治療領域預計在預測期內年複合成長率最高，達到 25.0%。細胞治療領域進一步分為幹細胞治療、細胞免疫治療及富血小板血漿治療。預計細胞免疫療法在預測期內的年複合成長率最高。該領域的快速成長是由癌症發病率增加、對 CAR T 細胞療法使用意識的提高以及基於細胞的免疫療法的批准和臨床試驗數量的增加所推動的。用於開發基於細胞的免疫療法的資金也在增加，進一步推動了市場成長。例如，2024年 5月，德國癌症支持組織向德國萊布尼茲免疫治療研究所（LIT）和雷根斯堡大學醫院（UKR）（德國）提供了 280萬美元（260萬歐元）的補助金。該撥款支持致力於使用乾細胞樣 CAR T 細胞治療晚期淋巴瘤患者的臨床研究。

在本報告調查的所有應用中，腫瘤學預計在預測期內年複合成長率最高，達到 26.5%。再生醫學提供了多種癌症治療方法，包括幹細胞療法、基因療法和組織工程。這些方法提供了個人化的治療選擇，並有助於最大限度地降低與傳統癌症治療相關的副作用風險。此外，癌症治療研究資金的增加也促進了這一領域的成長。例如，2024年2月，BioNTech SE（德國）向Autolus Therapeutics（英國）投資2億美元，建立策略合作以支持其癌症治療管道。

在本報告調查的所有最終用戶中，醫院和診所領域預計在預測期內年複合成長率最高。醫院和診所擁有完善的基礎設施、技術精湛的醫務人員、交通便利，並提供先進的治療，包括多種治療方法。因此，患者更有可能去醫院和診所就診。此外，許多醫院開設專門從事再生醫學的單位，以支持市場成長。例如，2023年4月，Jaslok醫院（印度）開設了恢復與再生醫學科，目的是治療複雜疾病。該部門提供用於骨科和關節疾病的各種基於細胞的治療的骨科生物製劑，以及用於骨科、血管和美容應用的富血小板血漿療法。

對全球再生醫學市場區域狀況的詳細分析提供了五個主要地區（北美、歐洲、亞太地區、拉丁美洲、中東和非洲）的詳細定性和定量見解，並提供了主要國家的覆蓋範圍。預計亞太地區在預測期內年複合成長率最高，達 25.0%。到2024年，日本預計將佔據亞太再生醫學市場的最大佔有率。日本龐大的市場佔有率歸因於其65歲以上人口眾多、政府為引進再生醫學所做的努力以及再生醫學審批的支持性監管框架。例如，日本引進了再生醫學的有條件批准制度，允許公司更快地將新療法推向市場。國家醫療保健系統也涵蓋這些新療法，進一步激勵外國公司將其產品引進日本。

調查範圍：

再生醫學市場評估：依產品分類

  • 基因治療
  • 細胞療法
    • 幹細胞療法
  • 家庭療法
  • 同質療法
    • 富血小板血漿療法
    • 基於細胞的免疫療法
  • 組織工程

再生醫學市場評估：依應用分類

  • 循環系統
  • 眼科
  • 腫瘤學
  • 神經病學
  • 免疫/炎症
  • 肌肉骨骼系統
  • 皮膚科
  • 其他用途

注意：其他用途包括傷口治療、整形外科和血液疾病。

再生醫學市場評估：依最終用戶

  • 醫院和診所
  • 門診手術中心

再生醫學市場評估：依地區

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 瑞士
    • 荷蘭
    • 瑞典
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 中東、非洲

目錄

第1章 簡介

第2章 研究方法

第3章 執行摘要

第4章 市場洞察

  • 市場概覽
  • 影響市場成長的因素
    • 促進因素
      • 新再生醫學核准
      • 增加再生醫學發展資金
      • 拓展再生醫學在新治療領域的應用
    • 抑制因素
      • 有關幹細胞的倫理問題
    • 機會
      • 對個人化醫療的需求不斷增加
    • 課題
      • 再生醫學製造的複雜性
    • 因素分析
  • 趨勢
    • 3D生物列印在再生醫學的應用
    • 人工智慧工具在再生醫學開發中的整合
    • 誘導多能幹細胞
  • 監理分析
    • 北美
      • 美國
      • 加拿大
    • 亞太地區
      • 日本
      • 中國
      • 印度
    • 歐洲
    • 中東、非洲
    • PRP 資格標準
  • 波特五力分析
  • 投融資場景
  • 管道分析

第5章 再生醫學市場評估：依產品

  • 摘要
  • 細胞療法
    • 基於細胞的免疫療法
    • 幹細胞療法
      • 同質療法
      • 家庭療法
    • 富血小板血漿療法
  • 基因治療
  • 組織工程產品

第6章 再生醫學市場評估：依應用

  • 摘要
  • 肌肉骨骼系統
  • 腫瘤學
  • 眼科
  • 免疫/炎症
  • 神經病學
  • 皮膚科
  • 心臟病學
  • 其他用途

第7章 再生醫學市場評估：依最終用戶

  • 簡介
  • 醫院/診所
  • 門診手術中心

第8章 再生醫學市場評估：依地區

  • 摘要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 瑞士
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他拉丁美洲地區
  • 中東、非洲

第9章 競爭分析

  • 摘要
  • 主要成長策略
  • 競爭基準測試
  • 競爭儀表板
    • 行業領導者
    • 市場差異化因素
    • 領先企業
    • 新興公司
  • 市場佔有率分析（2023年）
    • Novartis AG（Switzerland）
    • Kite Pharma, Inc.（U.S.）
    • Biogen, Inc.（U.S.）
    • Bristol-Myers Squibb Company（U.S.）
    • Janssen Global Services, LLC（U.S.）

第10章 公司簡介

  • Novartis AG
  • Kite Pharma, Inc.（A Subsidiary of Gilead Sciences, Inc.）
  • Janssen Global Services, LLC（A Subsidiary of Johnson & Johnson）
  • Bristol-Myers Squibb Company
  • Biogen Inc.
  • Smith & Nephew Plc
  • Amgen Inc.
  • Vericel Corporation
  • Integra Lifesciences Holdings Corporation
  • Pfizer Inc.
  • AbbVie Inc.
  • Sarepta Therapeutics, Inc.
  • Spark Therapeutics, Inc.（A Subsidiary of F. Hoffmann-La Roche Ag）
  • CORESTEMCHEMON, Inc.
  • CSL Behring, LLC（A Subsidiary of CSL Limited）
  • Takeda Pharmaceutical Company Limited
  • Ferring Pharmaceuticals
  • Medtronic plc
  • Bluebird Bio, Inc.
  • Vertex Pharmaceuticals Incorporated

（註：包含前5名公司的SWOT分析）

第11章 附錄

Product Code: MRHC - 1041181

Regenerative Medicine Market Size, Share, Forecast, & Trends Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User-Global Forecast to 2031

The global regenerative medicine market is projected to reach $37.27 billion by 2031 at a CAGR of 21.5% from 2024 to 2031.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities.

The growth of the global regenerative medicine market is driven by increasing approvals for new regenerative medicines, advancements in regenerative medicine, the rising incidence of chronic diseases, increasing funding for regenerative medicine development, and the growing applications of regenerative medicine in newer therapeutic areas. However, high treatment costs and ethical issues related to stem cells restrain the growth of this market.

Furthermore, the rising demand for personalized medicines, the increasing number of organ transplant procedures, and the strong product pipeline for regenerative medicines are expected to generate market growth opportunities. However, unfavorable reimbursement policies, complexities in the manufacture of regenerative medicines, and the lack of standardized frameworks for the safety & efficacy of regenerative medicines are major challenges in the global regenerative medicine market.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry in the last three to four years (2020-2024). The key players operating in the regenerative medicine market are Novartis AG (Switzerland), Biogen Inc. (U.S.), Kite Pharma, Inc. (U.S.), Spark Therapeutics, Inc. (U.S.), Integra LifeSciences Corporation (U.S.), Sarepta Therapeutics, Inc. (U.S.), Takeda Pharmaceutical Company Limited (Japan), Amgen Inc. (U.S.), CORESTEMCHEMON Inc. (South Korea), Smith & Nephew plc (England), Vertex Pharmaceuticals Incorporated (U.S.), CSL Behring, LLC (U.S.), Janssen Global Services, LLC (U.S.), Medtronic plc (Ireland), AbbVie Inc. (U.S.), Bristol-Myers Squibb Company (U.S.), Ferring Pharmaceuticals A/S (Sweden), Pfizer Inc. (U.S.), bluebird bio Inc. (U.S.), and Vericel Corporation (U.S.).

Among all the products studied in this report, the cell therapy segment is projected to register the highest CAGR of 25.0% during the forecast period. The cell therapy segment is further segmented into stem cell therapy, cell-based immunotherapy, and platelet-rich plasma therapy. Cell-based immunotherapy is projected to register the highest CAGR during the forecast period. The rapid growth of this segment is attributed to the increasing cancer prevalence, rising awareness regarding the use of CAR T-cell therapy, and rising number of approvals & clinical trials for cell-based immunotherapy. The funding for the development of cell-based immunotherapy is also increasing, further driving the market growth. For instance, in May 2024, German Cancer Aid provided a $2.8 million (€2.6 million) grant to the Leibniz Institute for Immunotherapy (LIT) and University Hospital Regensburg (UKR) (Germany). The funding was earmarked for a clinical study focused on the use of stem-like CAR T-cells to treat patients with advanced lymphomas.

Among all the applications studied in this report, the oncology segment is projected to register the highest CAGR of 26.5% during the forecast period. Regenerative medicine offers various approaches, such as stem cell therapy, gene therapy, and tissue engineering, for treating cancer. These approaches provide personalized treatment options and help minimize the risk of side effects associated with traditional cancer treatments. Additionally, the rising funding for cancer treatment research contributes to the growth of this segment. For instance, in February 2024, BioNTech SE (Germany) invested USD 200 million in Autolus Therapeutics (U.K.) and established a strategic collaboration to support the cancer therapy pipeline.

Among all the end users studied in this report, the hospitals and clinics segment is projected to register the highest CAGR during the forecast period. Hospitals & clinics have developed infrastructure and highly skilled healthcare professionals, are easily accessible, and offer advanced treatments, including various therapies. Hence, patients are more inclined toward visiting hospitals & clinics. Many hospitals are also launching dedicated units for regenerative medicine, driving market growth. For instance, in April 2023, Jaslok Hospital (India) opened a Restorative and Regenerative Medicine Department aimed at treating complex diseases. This department offers orthobiologics for various cell-based treatments for bone and joint disorders, as well as platelet-rich plasma therapies for orthopedic, vascular, and cosmetic applications.

An in-depth analysis of the geographical scenario of the global regenerative medicine market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. Asia-Pacific is projected to register the highest CAGR of 25.0% during the forecast period. In 2024, Japan is expected to account for the largest share of the regenerative medicine market in Asia-Pacific. The large market share of Japan is attributed to the large population base aged 65 and older, government initiatives for the adoption of regenerative medicine, and supportive regulatory framework for the approval of regenerative medicine. For instance, Japan has implemented a conditional approval system for regenerative medicine, allowing companies to bring new therapies to market more quickly. The national healthcare system also covers these new therapies, providing further incentives for foreign companies to introduce their products in Japan.

Scope of the Report:

Regenerative Medicine Market Assessment-by Product

  • Gene Therapy
  • Cell Therapy
    • Stem Cell Therapy
  • Autologous Therapy
  • Allogenic Therapy
    • Platelet Rich Plasma Therapy
    • Cell-based Immunotherapy
  • Tissue Engineering

Regenerative Medicine Market Assessment-by Application

  • Cardiology
  • Ophthalmology
  • Oncology
  • Neurology
  • Immunology & Inflammation
  • Musculoskeletal
  • Dermatology
  • Other Applications

Note: Other Applications include wound care, orthopedics, and blood disorders

Regenerative Medicine Market Assessment-by End User

  • Hospitals & Clinics
  • Ambulatory Surgical Centers

Regenerative Medicine Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Switzerland
    • Netherlands
    • Sweden
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Process
  • 2.2. Data Collection and Validation Process
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews With Key Opinion Leaders from the Industry
  • 2.3. Market Sizing & Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Factors Affecting Market Growth
    • 4.2.1. Drivers
      • 4.2.1.1. Approvals for New Regenerative Medicines
      • 4.2.1.2. Increasing Funding for Regenerative Medicine Development
      • 4.2.1.3. Increasing Applications of Regenerative Medicine in Newer Therapy Areas
    • 4.2.2. Restraints
      • 4.2.2.1. Ethical Issues Related to Stem Cells
    • 4.2.3. Opportunities
      • 4.2.3.1. Rising Demand for Personalized Medicines
    • 4.2.4. Challenges
      • 4.2.4.1. Complexities in the Manufacture of Regenerative Medicines
    • 4.2.5. Factor Analysis
  • 4.3. Trends
    • 4.3.1. Utilization of 3D Bioprinting in Regenerative Medicine
    • 4.3.2. Integration of AI Tools in Regenerative Medicine Development
    • 4.3.3. Induced Pluripotent Stem Cells
  • 4.4. Regulatory Analysis
    • 4.4.1. North America
      • 4.4.1.1. U.S.
      • 4.4.1.2. Canada
    • 4.4.2. Asia-Pacific
      • 4.4.2.1. Japan
      • 4.4.2.2. China
      • 4.4.2.3. India
    • 4.4.3. Europe
    • 4.4.4. Middle East & Africa
    • 4.4.5. PRP Qualification Criteria
  • 4.5. Porter's Five Forces Analysis
    • 4.5.1. Bargaining Power of Suppliers
    • 4.5.2. Bargaining Power of Buyers
    • 4.5.3. Threat of Substitutes
    • 4.5.4. Threat of New Entrants
    • 4.5.5. Degree of Competition
  • 4.6. Investment and Funding Scenario
  • 4.7. Pipeline Analysis

5. Regenerative Medicine Market Assessment-by Product

  • 5.1. Overview
  • 5.2. Cell Therapy
    • 5.2.1. Cell-based Immunotherapy
    • 5.2.2. Stem Cell Therapy
      • 5.2.2.1. Allogenic Therapy
      • 5.2.2.2. Autologous Therapy
    • 5.2.3. Platelet-rich Plasma Therapy
  • 5.3. Gene Therapy
  • 5.4. Tissue Engineering Products

6. Regenerative Medicine Market Assessment-by Application

  • 6.1. Overview
  • 6.2. Musculoskeletal
  • 6.3. Oncology
  • 6.4. Ophthalmology
  • 6.5. Immunology & Inflammation
  • 6.6. Neurology
  • 6.7. Dermatology
  • 6.8. Cardiology
  • 6.9. Other Applications

7. Regenerative Medicine Market Assessment-by End User

  • 7.1. Introduction
  • 7.2. Hospitals & Clinics
  • 7.3. Ambulatory Surgical Centers

8. Regenerative Medicine Market Assessment-by Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. U.K.
    • 8.3.3. France
    • 8.3.4. Switzerland
    • 8.3.5. Italy
    • 8.3.6. Spain
    • 8.3.7. Netherlands
    • 8.3.8. Sweden
    • 8.3.9. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. Australia
    • 8.4.4. India
    • 8.4.5. South Korea
    • 8.4.6. Rest of Asia-Pacific
  • 8.5. Latin America
    • 8.5.1. Brazil
    • 8.5.2. Mexico
    • 8.5.3. Rest of Latin America
  • 8.6. Middle East & Africa

9. Competition Analysis

  • 9.1. Overview
  • 9.2. Key Growth Strategies
  • 9.3. Competitive Benchmarking
  • 9.4. Competitive Dashboard
    • 9.4.1. Industry Leaders
    • 9.4.2. Market Differentiators
    • 9.4.3. Vanguards
    • 9.4.4. Emerging Companies
  • 9.5. Market Share Analysis (2023)
    • 9.5.1. Novartis AG (Switzerland)
    • 9.5.2. Kite Pharma, Inc. (U.S.)
    • 9.5.3. Biogen, Inc. (U.S.)
    • 9.5.4. Bristol-Myers Squibb Company (U.S.)
    • 9.5.5. Janssen Global Services, LLC (U.S.)

10. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis*)

  • 10.1. Novartis AG
  • 10.2. Kite Pharma, Inc. (A Subsidiary of Gilead Sciences, Inc.)
  • 10.3. Janssen Global Services, LLC (A Subsidiary of Johnson & Johnson)
  • 10.4. Bristol-Myers Squibb Company
  • 10.5. Biogen Inc.
  • 10.6. Smith & Nephew Plc
  • 10.7. Amgen Inc.
  • 10.8. Vericel Corporation
  • 10.9. Integra Lifesciences Holdings Corporation
  • 10.10. Pfizer Inc.
  • 10.11. AbbVie Inc.
  • 10.12. Sarepta Therapeutics, Inc.
  • 10.13. Spark Therapeutics, Inc. (A Subsidiary of F. Hoffmann-La Roche Ag)
  • 10.14. CORESTEMCHEMON, Inc.
  • 10.15. CSL Behring, LLC (A Subsidiary of CSL Limited)
  • 10.16. Takeda Pharmaceutical Company Limited
  • 10.17. Ferring Pharmaceuticals
  • 10.18. Medtronic plc
  • 10.19. Bluebird Bio, Inc.
  • 10.20. Vertex Pharmaceuticals Incorporated

(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

  • Table 1 U.S. FDA-Approved Cell & Gene Therapy Products (As of August 2024)
  • Table 2 Estimated Number of New Cancer Cases, by Region, 2022-2030 (Thousand)
  • Table 3 Comparison of Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation
  • Table 4 Risk Classification of Regenerative Medicines, by Type and Class
  • Table 5 Authorities/Organizations Funding and Investing In Regenerative Medicine-related Research & Development
  • Table 6 Regenerative Medicine Market: Pipeline Analysis
  • Table 7 Global Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 8 Estimated Number of New Leukemia Cases, by Region, 2022-2030 (Thousands)
  • Table 9 Global Regenerative Medicine Market for Cell Therapy, by Type, 2022-2031 (USD Million)
  • Table 10 Global Regenerative Medicine Market for Cell Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Companies Offering Cell-Based Immunotherapy Solutions
  • Table 12 Global Regenerative Medicine Market for Cell-Based Immunotherapy, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Companies Offering Stem Cell Therapy Solutions
  • Table 14 Characteristics Features of Stem Cell Therapy for Regenerative Medicine
  • Table 15 Global Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 16 Global Regenerative Medicine Market for Stem Cell Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Companies Offering Allogenic Therapy Solutions
  • Table 18 Global Regenerative Medicine Market for Allogenic Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 19 Companies Offering Autologous Cell Therapy
  • Table 20 Global Regenerative Medicine Market for Autologous Cell Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Companies Offering Platelet-Rich Plasma (PRP) Therapy
  • Table 22 Global Regenerative Medicine for Platelet-Rich Plasma (PRP) Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Companies Offering Gene Therapy Products
  • Table 24 Global Regenerative Medicine Market for Gene Therapy, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Companies Offering Tissue Engineering Products
  • Table 26 Global Regenerative Medicine Market for Tissue Engineering Products, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 28 Global Regenerative Medicine Market for Musculoskeletal Disorders, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Regenerative Medicine Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Regenerative Medicine Market for Ophthalmology, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Regenerative Medicine Market for Immunology & Inflammation, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global Regenerative Medicine Market for Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Regenerative Medicine Market for Dermatology, by Country/Region, 2022-2031 (USD Million)
  • Table 34 Global Regenerative Medicine Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Regenerative Medicine Market for Other Applications, by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 37 Global Regenerative Medicine Market for Hospitals & Clinics, by Country/Region, 2022-2031 (USD Million)
  • Table 38 Global Regenerative Medicine Market for Ambulatory Surgical Centers, by Country/Region, 2022-2031 (USD Million)
  • Table 39 Global Regenerative Medicine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 40 North America: Regenerative Medicine Market, by Country, 2022-2031 (USD Million)
  • Table 41 North America: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 42 North America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 43 North America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 44 North America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 45 North America: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 46 U.S.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 47 U.S.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 48 U.S.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 49 U.S.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 50 U.S.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 51 Canada: Approved Regenerative Medicine, 2021-2024
  • Table 52 Canada: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 53 Canada: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 54 Canada: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 55 Canada: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 56 Canada: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 57 Europe: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
  • Table 58 Europe: Regenerative Medicine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 59 Europe: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 60 Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 61 Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 62 Europe: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 63 Europe: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 64 Germany: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 65 Germany: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 66 Germany: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 67 Germany: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 68 Germany: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 69 U.K.: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 70 U.K.: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 71 U.K.: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 72 U.K.: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 73 U.K.: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 74 France: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 75 France: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 76 France: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 77 France: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 78 France: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 79 Switzerland: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 80 Switzerland: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 81 Switzerland: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 82 Switzerland: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 83 Switzerland: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 84 Italy: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 85 Italy: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 86 Italy: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 87 Italy: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 88 Italy: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 89 Spain: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 90 Spain: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 91 Spain: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 92 Spain: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 93 Spain: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 94 Netherlands: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 95 Netherlands: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 96 Netherlands: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 97 Netherlands: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 98 Netherlands: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 99 Sweden: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 100 Sweden: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 101 Sweden: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 102 Sweden: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 103 Sweden: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 104 Rest of Europe: Estimated Number of New Cancer Cases, by Country, 2022 Vs. 2030
  • Table 105 Rest of Europe: Recent Developments In The Regenerative Medicine Market
  • Table 106 Rest of Europe: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 107 Rest of Europe: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 108 Rest of Europe: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 109 Rest of Europe: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 110 Rest of Europe: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 111 Asia-Pacific: Regenerative Medicine Sector Data, Q2 2024 Vs. Q1 2023
  • Table 112 Asia-Pacific: Regenerative Medicine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 113 Asia-Pacific: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 114 Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 115 Asia-Pacific: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 116 Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 117 Asia-Pacific: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 118 Japan: Approved Regenerative Medicine
  • Table 119 Japan: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 120 Japan: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 121 Japan: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 122 Japan: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 123 Japan: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 124 China: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 125 China: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 126 China: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 127 China: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 128 China: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 129 Australia: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 130 Australia: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 131 Australia: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 132 Australia: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 133 Australia: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 134 India: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 135 India: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 136 India: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 137 India: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 138 India: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 139 South Korea: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 140 South Korea: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 141 South Korea: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 142 South Korea: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 143 South Korea: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 144 Rest of Asia-Pacific: Recent Developments in Regenerative Medicine Market, by Country
  • Table 145 Rest of Asia-Pacific: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 146 Rest of Asia-Pacific: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 147 Rest of Asia-Pacific: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 148 Rest of Asia-Pacific: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 149 Rest of Asia-Pacific: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 150 Latin America: Regenerative Medicine Market, by Country/Region, 2022-2031 (USD Million)
  • Table 151 Latin America: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 152 Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 153 Latin America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 154 Latin America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 155 Latin America: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 156 Brazil: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 157 Brazil: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 158 Brazil: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 159 Brazil: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 160 Brazil: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 161 Mexico: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 162 Mexico: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 163 Mexico: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 164 Mexico: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 165 Mexico: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 166 Rest of Latin America: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 167 Rest of Latin America: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 168 Rest of Latin America: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 169 Rest of Latin America: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 170 Rest of Latin America: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 171 Middle East & Africa: Regenerative Medicine Market, by Product, 2022-2031 (USD Million)
  • Table 172 Middle East & Africa: Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 173 Middle East & Africa: Stem Cell Therapy Market, by Type, 2022-2031 (USD Million)
  • Table 174 Middle East & Africa: Regenerative Medicine Market, by Application, 2022-2031 (USD Million)
  • Table 175 Middle East & Africa: Regenerative Medicine Market, by End User, 2022-2031 (USD Million)
  • Table 176 Recent Developments, by Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Secondary Sources Referenced for this Study.
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Sizing And Growth Forecast Approach
  • Figure 7 Global Regenerative Medicine Market, by Product, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Regenerative Medicine Market, by Application, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Regenerative Medicine Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 10 Global Regenerative Medicine Market, by Geography
  • Figure 11 Impact Analysis of Market Dynamics
  • Figure 12 NIH Funding for Regenerative Medicine, 2019-2025 (USD Million)
  • Figure 13 Japan: Regenerative Medicines Regulatory Pathway
  • Figure 14 India: Approval Pathway for Regenerative Medicines
  • Figure 15 Saudi Arabia: Drug Licensing - Marketing Authorization Process
  • Figure 16 Porter's Five Forces Analysis
  • Figure 17 Investments In Regenerative Medicine, 2017-2023 (USD Billion)
  • Figure 18 Global Regenerative Medicine Market, by Product, 2024 Vs. 2031 (USD Million)
  • Figure 19 Cell-based Immunotherapy Workflow
  • Figure 20 Global Regenerative Medicine Market, by Application, 2024 VS. 2031 (USD Million)
  • Figure 21 Global Regenerative Medicine Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 22 Regenerative Medicine Market, by Geography, 2024 VS. 2031 (USD Million)
  • Figure 23 North America: Regenerative Medicine Market Snapshot
  • Figure 24 Europe: Regenerative Medicine Market Snapshot
  • Figure 25 Asia-Pacific: Regenerative Medicine Market Snapshot
  • Figure 26 Latin America: Regenerative Medicine Market Snapshot
  • Figure 27 Key Growth Strategies Adopted by Leading Players, 2021-2024
  • Figure 28 Regenerative Medicine Market: Competitive Benchmarking, by Product
  • Figure 29 Regenerative Medicine Market: Competitive Benchmarking, by Region
  • Figure 30 Competitive Dashboard: Regenerative Medicine Market
  • Figure 31 Global Regenerative Medicine Market Share Analysis, by Key Players (2023)
  • Figure 32 Novartis AG: Financial Snapshot (2023)
  • Figure 33 Gilead Sciences, Inc.: Financial Overview (2023)
  • Figure 34 Johnson & Johnson.: Financial Overview (2023)
  • Figure 35 Bristol-Myers Squibb Company: Financial Overview (2023)
  • Figure 36 Biogen Inc.: Financial Snapshot (2023)
  • Figure 37 Smith & Nephew Plc: Financial Overview (2023)
  • Figure 38 Amgen Inc.: Financial Overview (2023)
  • Figure 39 Vericel CORPORATION.: Financial Overview (2023)
  • Figure 40 Integra Lifesciences Holdings Corporation.: Financial Snapshot (2023)
  • Figure 41 Pfizer Inc.: Financial Snapshot (2023)
  • Figure 42 AbbVie Inc: Financial Overview (2023)
  • Figure 43 Sarepta Therapeutics, Inc.: Financial Snapshot (2023)
  • Figure 44 F. Hoffmann-La Roche AG: Financial Snapshot (2023)
  • Figure 45 CORESTEMCHEMON, Inc.: Financial Overview (2022)
  • Figure 46 CSL LIMITED: Financial Overview (2024)
  • Figure 47 Takeda Pharmaceutical Company Limited: Financial Overview (2023)
  • Figure 48 Ferring Pharmaceuticals: Financial Overview (2023)
  • Figure 49 Medtronic plc: Financial Overview (2024)
  • Figure 50 bluebird bio, Inc.: Financial Overview (2023)
  • Figure 51 Vertex Pharmaceuticals Incorporated: Financial Overview (2023)